These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26048791)

  • 1. Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.
    Han S; Narayanan S; Kim SH; Calderon I; Zhu X; Kawasaki A; Yue D; Lehmann J; Wong A; Buzard DJ; Semple G; Carroll C; Chu ZL; Al-Sharmma H; Shu HH; Tung SF; Unett DJ; Behan DP; Yoon WH; Morgan M; Usmani KA; Chen C; Sadeque A; Leonard JN; Jones RM
    Bioorg Med Chem Lett; 2015 Aug; 25(15):3034-8. PubMed ID: 26048791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of a novel series of potent and orally bioavailable GPR119 agonists.
    Koshizawa T; Morimoto T; Watanabe G; Watanabe T; Yamasaki N; Sawada Y; Fukuda T; Okuda A; Shibuya K; Ohgiya T
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3249-3253. PubMed ID: 28648463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists.
    Matsuda D; Kawamura M; Kobashi Y; Shiozawa F; Suga Y; Fusegi K; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N
    Bioorg Med Chem; 2018 May; 26(8):1832-1847. PubMed ID: 29486951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
    Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
    Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of oxadiazole derivatives with a spirocyclic cyclohexane structure as novel GPR119 agonists.
    Harada K; Mizukami J; Watanabe T; Mori G; Ubukata M; Suwa K; Fukuda S; Negoro T; Sato M; Inaba T
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2100-2106. PubMed ID: 31288965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
    Semple G; Lehmann J; Wong A; Ren A; Bruce M; Shin YJ; Sage CR; Morgan M; Chen WC; Sebring K; Chu ZL; Leonard JN; Al-Shamma H; Grottick AJ; Du F; Liang Y; Demarest K; Jones RM
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1750-5. PubMed ID: 22264481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.
    Brocklehurst KJ; Broo A; Butlin RJ; Brown HS; Clarke DS; Davidsson Ö; Goldberg K; Groombridge SD; Kelly EE; Leach A; McKerrecher D; O'Donnell C; Poucher S; Schofield P; Scott JS; Teague J; Westgate L; Wood MJ
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7310-6. PubMed ID: 22061639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic potential of GPR119 agonists for type 2 diabetes.
    Ohishi T; Yoshida S
    Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of novel and potent GPR119 agonists with a spirocyclic structure.
    Harada K; Mizukami J; Kadowaki S; Matsuda I; Watanabe T; Oe Y; Kodama Y; Aoki K; Suwa K; Fukuda S; Yata S; Inaba T
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1228-1233. PubMed ID: 29519733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPR119 agonists for the treatment of type 2 diabetes.
    Jones RM; Leonard JN; Buzard DJ; Lehmann J
    Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.
    Semple G; Fioravanti B; Pereira G; Calderon I; Uy J; Choi K; Xiong Y; Ren A; Morgan M; Dave V; Thomsen W; Unett DJ; Xing C; Bossie S; Carroll C; Chu ZL; Grottick AJ; Hauser EK; Leonard J; Jones RM
    J Med Chem; 2008 Sep; 51(17):5172-5. PubMed ID: 18698756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
    Wacker DA; Wang Y; Broekema M; Rossi K; O'Connor S; Hong Z; Wu G; Malmstrom SE; Hung CP; LaMarre L; Chimalakonda A; Zhang L; Xin L; Cai H; Chu C; Boehm S; Zalaznick J; Ponticiello R; Sereda L; Han SP; Zebo R; Zinker B; Luk CE; Wong R; Everlof G; Li YX; Wu CK; Lee M; Griffen S; Miller KJ; Krupinski J; Robl JA
    J Med Chem; 2014 Sep; 57(18):7499-508. PubMed ID: 25208139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lead generation and optimization of novel GPR119 agonists with a spirocyclic cyclohexane structure.
    Harada K; Mizukami J; Watanabe T; Mori G; Ubukata M; Suwa K; Fukuda S; Negoro T; Sato M; Inaba T
    Bioorg Med Chem Lett; 2019 Feb; 29(3):373-379. PubMed ID: 30587450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
    Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists.
    Zuo Z; Chen M; Shao X; Qian X; Liu X; Zhou X; Xiang J; Deng P; Li Y; Jie H; Liu C; Cen X; Xie Y; Zhao Y
    Bioorg Med Chem Lett; 2020 Feb; 30(4):126855. PubMed ID: 31898998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
    Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M
    Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice.
    Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
    Biochem Biophys Res Commun; 2010 Nov; 402(2):280-5. PubMed ID: 20937249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
    Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
    Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists.
    Katamreddy SR; Carpenter AJ; Ammala CE; Boros EE; Brashear RL; Briscoe CP; Bullard SR; Caldwell RD; Conlee CR; Croom DK; Hart SM; Heyer DO; Johnson PR; Kashatus JA; Minick DJ; Peckham GE; Ross SA; Roller SG; Samano VA; Sauls HR; Tadepalli SM; Thompson JB; Xu Y; Way JM
    J Med Chem; 2012 Dec; 55(24):10972-94. PubMed ID: 23214471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.